Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: 22q11.2 Deletion Syndrome
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on 22q11.2 Deletion Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: 22q11.2 Deletion Syndrome (22q11.2DS)

Executive summary

22q11.2 deletion syndrome (22q11.2DS) is a recurrent genomic disorder caused by a heterozygous (hemizygous) microdeletion at chromosome 22q11.2. It is among the most common microdeletion syndromes, with typical estimates of ~1:3,000–1:6,000 live births (often summarized near ~1:4,000), though prevalence varies by ascertainment and population studies. Clinically, it is multisystem and highly variable, with prominent congenital heart disease, palatal anomalies, hypocalcemia/hypoparathyroidism, and thymic hypoplasia with T-cell lymphopenia; later-onset neurodevelopmental and neuropsychiatric outcomes are common and include markedly elevated schizophrenia risk. Recent (2023–2024) work emphasizes standardized immunologic management (including vaccine decision thresholds), increased early detection via newborn TREC screening, expanding—but imperfect—prenatal cfDNA screening, and mechanistic models incorporating miRNA/epigenetic dysregulation and gene–environment interaction.

Table: This table compiles high-value identifiers, epidemiology, genotype architecture, phenotype frequencies, prognosis metrics, and diagnostic/screening performance for 22q11.2 deletion syndrome. It is designed as a quick-reference evidence grid for knowledge-base curation and report drafting.

1. Disease information

1.1 Overview (what is the disease?)

22q11.2 deletion syndrome is a genetic syndrome due to a hemizygous deletion in 22q11.2, historically described under multiple partially overlapping clinical labels (DiGeorge syndrome, velocardiofacial syndrome). In the immunology guideline context, it is considered a major cause of “defects in thymic development (DTD)” and is classically associated with the DiGeorge phenotype triad. A citable statement from the guideline: “The classic phenotypic triad of DGS consists of conotruncal heart defects, hypocalcemia due to hypoparathyroidism, and T cell deficiency due to thymic hypoplasia.” (Mustillo et al., 2023, Journal of Clinical Immunology; URL: https://doi.org/10.1007/s10875-022-01418-y) (mustillo2023clinicalpracticeguidelines pages 1-2).

1.2 Key identifiers

OMIM identifiers explicitly present in retrieved sources include: - DiGeorge syndrome: OMIM #188400 (Soster et al., 2023; Cong et al., 2025) (soster2023positivecfdnascreening pages 1-2, cong2025evaluatingtheeffectiveness pages 1-5) - Velocardiofacial syndrome (VCFS): OMIM #192430 (Soster et al., 2023) (soster2023positivecfdnascreening pages 1-2) - One prenatal screening paper also lists “22q11.2 DS, OMIM 611867” (Cong et al., 2025) (cong2025evaluatingtheeffectiveness pages 1-5).

Not available in the retrieved full texts: ICD-10/ICD-11 codes, MeSH identifier strings, Orphanet ID, and MONDO ID were not explicitly stated in the retrieved documents and thus cannot be cited from this evidence set.

1.3 Synonyms and alternative names

Commonly used synonyms: - DiGeorge syndrome (DGS) (soster2023positivecfdnascreening pages 1-2) - Velocardiofacial syndrome (VCFS) (soster2023positivecfdnascreening pages 1-2) - CATCH22 (cardiac defect, abnormal facies, thymic hypoplasia, cleft palate, hypocalcemia) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4) - “Chromosome 22q11.2 microdeletion syndrome,” “22q11.2del,” “DiGeorge anomaly” (mustillo2023clinicalpracticeguidelines pages 1-2, mustillo2023clinicalpracticeguidelines pages 2-4)

1.4 Evidence sources (patient-level vs aggregated)

The knowledge in this report derives from: - Aggregated guideline and review sources (e.g., Mustillo 2023 guideline; Szczawińska-Popłonyk 2023; Cillo 2024) (mustillo2023clinicalpracticeguidelines pages 1-2, szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, cillo2024understandingthevariability pages 1-2) - Population-based registries/cohorts (e.g., Danish iPSYCH case-cohort prevalence estimate; adult mortality cohort; Ontario administrative data linkage) (olsen2018prevalenceofrearrangements pages 1-3, van2019allcausemortalityand pages 4-6, malecki2026delineatingthetrajectory pages 1-2) - Clinical laboratory cohorts for prenatal screening performance (cfDNA/NIPS) (soster2023positivecfdnascreening pages 1-2, cong2025evaluatingtheeffectiveness pages 1-5)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): a recurrent hemizygous microdeletion in 22q11.2. The deletion arises through meiotic rearrangements mediated by non-allelic homologous recombination (NAHR) between low-copy repeats (LCR22s) in the region (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

Deletion classes and frequencies (typical vs nested): - A frequently cited architecture: ~90% have a ~2.54 Mb deletion between LCR22A and LCR22D affecting ~40 genes, with smaller proximal or nested deletions (A–B, A–C, B–D, C–D) comprising the remainder (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4). - Another recent review summarizes that ~85% carry the typical ~3 Mb deletion containing ~46 protein-coding genes (cillo2024understandingthevariability pages 1-2).

2.2 Risk factors

2.2.1 Genetic risk factors

• De novo occurrence dominates: ~90–95% of deletions are de novo (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).
• Familial inheritance occurs in ~10% (autosomal dominant transmission), with some sources noting broader reported ranges (6–28%) depending on ascertainment and deletion subtype (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).
• Key dosage-sensitive genes repeatedly highlighted include TBX1 and DGCR8, with CRKL implicated especially for cardiac/renal phenotypes and immune effects (du2020thegeneticsand pages 3-5, cillo2024understandingthevariability pages 7-8).

2.2.2 Environmental risk factors

Direct environmental causes for the deletion are not established (as expected for NAHR-mediated recurrent CNVs). However, environmental factors may modify phenotypic outcomes, particularly neuropsychiatric presentations (see Section 6: gene–environment interactions).

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

A 2024 translational epigenetic study (preprint) used a mouse deletion model with and without acute stress, identifying overlapping methylation/miRNA alterations and implicating Wnt-pathway differences associated with stress and psychosis within the context of the deletion (Jiao et al., 2024; URL: https://doi.org/10.1101/2024.06.23.24309352) (jiao2024epigeneticfactorsin pages 1-4).

3. Phenotypes (with HPO suggestions)

3.1 Core multisystem phenotype (current understanding)

Across 2023–2024 reviews, the phenotype is dominated by congenital anomalies plus evolving immune and neurodevelopmental sequelae: - Congenital heart disease (CHD): commonly ~60–80% in children (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5) and summarized as ~75% in an epigenetics-focused 2024 review (cillo2024understandingthevariability pages 3-5). - Palatal anomalies / velopharyngeal dysfunction: reported 30–80% in a 2023 review (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5) and 69–100% in a 2024 review (cillo2024understandingthevariability pages 3-5), with overt cleft palate ~11% and milder palatal dysfunction ~65% in another 2024 summary (cillo2024understandingthevariability pages 2-3). - Endocrine: hypocalcemia/hypoparathyroidism ~35% in one 2024 review (cillo2024understandingthevariability pages 3-5) and 50–65% in another (cillo2024understandingthevariability pages 2-3). - Immune: T-cell lymphopenia is common; guideline estimates suggest 67–80% have some T-cell lymphopenia, and ~0.5% have congenital athymia (mustillo2023clinicalpracticeguidelines pages 2-4). Complete DiGeorge/congenital athymia is <0.5–1.5% in reviews (cillo2024understandingthevariability pages 2-3). - Neurodevelopmental: developmental/learning problems ~70% (cillo2024understandingthevariability pages 3-5); neurodevelopmental delays can begin in infancy with later educational difficulties (cuturilo2026neurodevelopmentaldisordersin pages 1-2). - Neuropsychiatric: schizophrenia risk often cited ~25–30% in reviews (cillo2024understandingthevariability pages 2-3, cillo2024understandingthevariability pages 3-5). A meta-analysis provides more conservative pooled estimates of psychotic disorders overall (see Section 11).

3.2 Representative phenotype-to-HPO mapping (non-exhaustive)

Cardiac - Conotruncal heart defect — HPO suggestion: HP:0001701 (conotruncal heart malformation) - Tetralogy of Fallot — HP:0001636 - Ventricular septal defect — HP:0001629 - Interrupted aortic arch — HP:0002556

Palate/speech - Cleft palate — HP:0000175 - Velopharyngeal insufficiency — HP:0000220 - Hypernasal speech — HP:0001611

Endocrine/metabolic - Hypocalcemia — HP:0002901 - Hypoparathyroidism — HP:0000828 - Hypothyroidism — HP:0000821

Immunology - T-cell lymphopenia — HP:0005404 - Thymic aplasia/hypoplasia — HP:0000777 - Recurrent infections — HP:0002719

Neurodevelopment/psychiatry - Global developmental delay — HP:0001263 - Intellectual disability — HP:0001249 - Autism — HP:0000717 - Attention deficit hyperactivity disorder — HP:0007018

(These HPO IDs are provided as ontology suggestions; the retrieved sources describe the corresponding clinical features and frequencies but do not list HPO IDs directly.)

3.3 Quality-of-life impact

In this evidence set, direct patient-reported QoL metrics for individuals with 22q11.2DS were not retrieved; however, caregiver QoL burden has been quantified in a 2025 caregiver survey, indicating substantial physical and social domain QoL reductions in caregivers (not patients) (olsen2018prevalenceofrearrangements pages 1-3). This suggests indirect but important real-world burden.

4. Genetic/Molecular information

4.1 Causal genomic event and genes

Causal variant class: recurrent copy-number deletion (structural variant) at 22q11.2 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4).

Key genes repeatedly implicated and/or discussed as central contributors: - TBX1 (transcription factor; central for many congenital malformations) (du2020thegeneticsand pages 3-5, du2020thegeneticsand pages 5-6) - DGCR8 (miRNA processing; affects global miRNA biogenesis) (cillo2024understandingthevariability pages 9-11, jiao2024epigeneticfactorsin pages 1-4) - CRKL (renal/cardiac and immune contributions noted in recent review) (cillo2024understandingthevariability pages 7-8) Other genes frequently listed in the region in a 2023 review include PRODH, COMT, CDC45, GP1BB, SNAP29, DGCR2, DGCR6/DGCR6L (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4).

4.2 Variant classification and origin

• The deletion is germline and generally classified as pathogenic.
• De novo in ~90–95% (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2);
• Inherited autosomal dominant in ~10% (cillo2024understandingthevariability pages 1-2).

4.3 Modifier mechanisms (dual diagnosis, unmasking)

A 2024 review notes that additional pathogenic variants outside the deleted region producing a “dual diagnosis” occur in ~1% of patients, and hemizygosity can unmask recessive conditions on the remaining allele (cillo2024understandingthevariability pages 1-2).

4.4 Epigenetic information

Recent reviews support the idea that epigenetic regulation contributes to phenotypic variability: - A 2024 review reports a methylation epi-signature distinguishing patients from controls (cillo2024understandingthevariability pages 1-2). - TBX1 is described as modulating chromatin accessibility and H3K4 monomethylation (H3K4me1) via recruitment of histone modifiers (cillo2024understandingthevariability pages 7-8).

5. Environmental information

5.1 Environmental/lifestyle contributors

No specific toxin/infection exposure causes were identified for the deletion event itself in the retrieved evidence. For neuropsychiatric outcomes, environmental variables (stress, parental factors, substance use) are discussed as potential modifiers in a 2022 literature review (Snihirova et al., 2022; URL: https://doi.org/10.3390/genes13112003) (snihirova2022environmentalinfluenceson pages 1-2).

6. Mechanism / pathophysiology

6.1 Upstream: formation of the deletion

The 22q11.2 region contains low-copy repeats (LCR22s) that predispose to NAHR-mediated rearrangements, generating recurrent deletions (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

GO suggestions (upstream mechanisms): - DNA recombination (GO:0006310) - Double-strand break repair (GO:0006302)

6.2 Developmental cascade to clinical manifestations

Pharyngeal apparatus disruption and organ maldevelopment: A highly cited genetics/epigenetics review links pathology to defective remodeling of the pharyngeal region during embryogenesis, affecting the second heart field and 3rd pharyngeal pouch derivatives (thymus, inferior parathyroids), providing a mechanistic chain for CHD + thymic hypoplasia + hypocalcemia (Du et al., 2020; URL: https://doi.org/10.3389/fgene.2019.01365) (du2020thegeneticsand pages 1-2).

TBX1 dosage effects (core developmental regulator): - “The congenital malformations associated with 22q11.2del are often linked to the haploinsufficiency of TBX1” and TBX1 regulates nearly ~2,000 genes in relevant progenitors (du2020thegeneticsand pages 3-5). - TBX1 interacts with chromatin modifiers (KMT2 family, BAF complex) and can influence BMP signaling through SMAD pathways (du2020thegeneticsand pages 5-6).

DGCR8 and miRNA-mediated network effects: - DGCR8 haploinsufficiency perturbs canonical miRNA biogenesis; miRNA disruptions are tied to synaptic/neurodevelopmental changes and immune dysregulation (cillo2024understandingthevariability pages 9-11, cillo2024understandingthevariability pages 1-2). - miR-185 (within the deleted region) targets neuronal SERCA2 and immune targets such as BTK/MZB1, linking dosage to Ca2+ homeostasis and B-cell receptor signaling phenotypes (cillo2024understandingthevariability pages 9-11).

Cell types (CL suggestions): - T cell — CL:0000084 - Thymic epithelial cell — CL:0002370 (key for thymopoiesis; consistent with thymic development defects) - Neural crest cell — CL:0000134 (implicated in pharyngeal arch development; referenced conceptually in TBX1/DGCR6 discussion) (du2020thegeneticsand pages 5-6)

6.3 Pathways highlighted in recent work

• Wnt signaling: epigenetic differences in Wnt pathway associated with stress and psychosis in the deletion context (jiao2024epigeneticfactorsin pages 1-4).
• PI3K/AKT appears in mechanistic discussion via miRNA targeting and signaling nodes (du2020thegeneticsand pages 3-5).

7. Anatomical structures affected (UBERON suggestions)

Primary organ systems: - Heart (conotruncal/outflow tract) — UBERON:0000948 - Thymus — UBERON:0002370 - Parathyroid gland — UBERON:0002110 - Palate/velopharynx — UBERON:0000165 (mouth) / UBERON:0001726 (palate) - Brain (neurodevelopmental/psychiatric manifestations) — UBERON:0000955

Localization and laterality: no consistent lateralization is characteristic in the retrieved evidence.

8. Temporal development

8.1 Onset

• Congenital presentation is common (CHD, palatal anomalies, hypocalcemia, thymic hypoplasia) (cillo2024understandingthevariability pages 2-3).
• Neurodevelopmental manifestations “typically begin in infancy with delayed motor and speech development and progress into school age” (Čuturilo et al., 2026) (cuturilo2026neurodevelopmentaldisordersin pages 1-2).

8.2 Progression/course

• Immune deficits can show partial recovery (“spontaneous immunocorrection” in partial forms) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 10-12).
• Neuropsychiatric risk (psychosis) increases with age (meta-analysis shows higher prevalence in adults) (provenzani2022prevalenceandincidence pages 1-5).
• Adult chronic disease burden (cardiometabolic, kidney disease) accrues early in adulthood (malecki2026delineatingthetrajectory pages 1-2).

9. Inheritance and population

9.1 Epidemiology

Prevalence estimates differ across studies: - Reviews/guidelines: ~1:3,000–1:6,000 live births (mustillo2023clinicalpracticeguidelines pages 2-4, soster2023positivecfdnascreening pages 1-2). - Population-based Danish estimate: ~1:3,672 (olsen2018prevalenceofrearrangements pages 1-3). - Minimum estimate incorporating prenatal + infant diagnoses (Victoria, Australia): ~1:4,558 births (hui2020aminimumestimate pages 10-11). - A 2024 review cites a “recent minimum estimate of 1 in 2,148 live births” (cillo2024understandingthevariability pages 1-2).

9.2 Inheritance pattern

• Autosomal dominant transmission is possible, but most cases are de novo (~90–95%) (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

10. Diagnostics

10.1 Clinical recognition

Clinical suspicion often arises from conotruncal CHD, palatal dysfunction, hypocalcemia, immune abnormalities, and characteristic facial features (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, cillo2024understandingthevariability pages 2-3).

10.2 Genetic testing (current practice)

• Chromosomal microarray (CMA) and FISH are described as traditional standard diagnostic tests (mustillo2023clinicalpracticeguidelines pages 2-4).
• FISH may miss atypical/distal deletions; CMA can detect copy-number imbalances genome-wide (mustillo2023clinicalpracticeguidelines pages 2-4).
• MLPA can validate deletion/duplication origin and help identify maternal CNVs in prenatal follow-up (cong2025evaluatingtheeffectiveness pages 5-10).

10.3 Newborn screening (real-world implementation)

• TREC-based newborn screening for SCID has increased detection of 22q11.2DS, though only ~3–15% of infants have abnormal TRECs using current cutoffs (biggs2023chromosome22q11.2deletion pages 5-7).

10.4 Prenatal screening: cfDNA/NIPS

• cfDNA screening has been available since 2013 for 22q11.2DS (soster2023positivecfdnascreening pages 1-2).
• Reported PPVs vary widely across studies (“18% to greater than 97%”) (soster2023positivecfdnascreening pages 2-3).
• In one laboratory cohort of 307 screen-positive samples, observed PPVs among those with diagnostic testing were 90.7%–99.4% (soster2023positivecfdnascreening pages 1-2).
• In an unselected cohort of 38,495 pregnancies (Nov 2022–Mar 2024), the PPV for 22q11.2 deletion calls was 47.06% (8/17 confirmed) and sensitivity was reported as 83.33%; maternal CNVs explained some discordant positives (cong2025evaluatingtheeffectiveness pages 1-5, cong2025evaluatingtheeffectiveness pages 14-18).

Expert consensus note: The ACMG has issued a conditional recommendation that screening for 22q11.2DS be offered to all patients (soster2023positivecfdnascreening pages 2-3).

11. Outcomes / prognosis

11.1 Mortality and survival

A major adult cohort study (Genetics in Medicine, 2019) reported: - Strongly increased mortality vs unaffected siblings (HR 8.86, 95% CI 2.87–27.37) (Van et al., 2019; URL: https://doi.org/10.1038/s41436-019-0509-y) (van2019allcausemortalityand pages 3-4). - Median age at death 46.4 years; all deaths before age 70 in the sample (van2019allcausemortalityand pages 4-6). - Cardiovascular causes accounted for 71% of deaths (sudden cardiac death, heart failure, arrhythmia) (van2019allcausemortalityand pages 4-6). - Major CHD was an independent mortality predictor; survival to age 45 was ~72% with major CHD vs ~95% without (van2019allcausemortalityand pages 1-2).

11.2 Adult chronic disease burden

A population-based Ontario matched cohort found accelerated accrual of cardiovascular conditions (RR 3.8) and increased incidence of hypertension and diabetes by age 18–24 (IRR 2.98 and 3.21, respectively) (Malecki et al., 2026; URL: https://doi.org/10.3389/fgene.2026.1737027) (malecki2026delineatingthetrajectory pages 1-2).

11.3 Psychiatric outcomes

A meta-analysis estimated: - Pooled prevalence of psychotic disorders: 11.50% (95% CI 9.40–14.00%), schizophrenia 9.70% (95% CI 6.50–14.20%) (Provenzani et al., 2022; URL: https://doi.org/10.1080/09540261.2022.2123273) (provenzani2022prevalenceandincidence pages 1-5). - Incidence: 10.60% over ~59 months follow-up (provenzani2022prevalenceandincidence pages 1-5).

12. Treatment / management

12.1 Immunology-focused management (2023 guideline and 2023 review)

Baseline and longitudinal immune evaluation (CBC, lymphocyte subsets including naïve/memory, quantitative immunoglobulins, proliferation where indicated) is recommended to stratify risk and guide vaccines/IGRT (biggs2023chromosome22q11.2deletion pages 5-7).

Live vaccine decision thresholds (practical implementation): - Guideline recommends MMR/varicella at ~1 year if immune criteria met, including absolute CD4 ≥400 cells/mm3, CD8 ≥200 cells/mm3, protective tetanus IgG after DTaP, and naïve T-cell predominance (mustillo2023clinicalpracticeguidelines pages 13-15). - A review provides similar thresholds using cell counts in SI units (total T cells >0.5×10^9/L; CD8+ >0.2×10^9/L; normal mitogen response) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 12-13).

Immunoglobulin replacement therapy (IGRT): most patients do not require IGRT; one cohort cited ~3% usage, with absolute indications in congenital athymia and CVID-like phenotypes (mustillo2023clinicalpracticeguidelines pages 16-17).

Antibiotic prophylaxis (selected): TMP/SMX regimens are discussed for PJP prophylaxis in athymic patients (mustillo2023clinicalpracticeguidelines pages 17-19).

Blood product precautions: for some with severe T-cell lymphopenia, use irradiated/leukocyte-reduced/CMV-negative products (mustillo2023clinicalpracticeguidelines pages 16-17).

12.2 Thymus transplantation for congenital athymia (complete DiGeorge)

Mustillo et al. (2023) summarize that thymic implant recipients can develop functional naïve T cells as early as 3–4 months, with protective reconstitution generally 6–12 months; reported survival after implant 72% (76/105) (mustillo2023clinicalpracticeguidelines pages 17-19). ClinicalTrials.gov trial records provide implementation thresholds and endpoints for cultured thymus implantation (NCT01220531) including severe T-cell lymphopenia definitions and follow-up schedule (NCT01220531 chunk 2).

12.3 Clinical trials (examples from ClinicalTrials.gov retrieved)

• Thymus transplantation safety/efficacy (NCT01220531; completed) (NCT01220531 chunk 2)
• Additional thymus transplantation studies (e.g., NCT00576407; completed) are present in the retrieved trial set (trial metadata retrieved in search output; full evidence not extracted beyond NCT01220531).

MAXO suggestions (examples): - Thymus transplantation — MAXO: thymus transplantation (term to be mapped in KB) - Immunoglobulin replacement therapy — MAXO: immunoglobulin replacement - Antibiotic prophylaxis — MAXO: antimicrobial prophylaxis - Genetic counseling — MAXO: genetic counseling

13. Prevention

Because 22q11.2DS is primarily due to de novo NAHR-mediated deletion, primary prevention of the deletion event is not currently feasible based on this evidence set.

Secondary/tertiary prevention approaches in practice include: - Early detection via newborn TREC screening (improves time to diagnosis) (biggs2023chromosome22q11.2deletion pages 5-7). - Prenatal screening (cfDNA/NIPS) with confirmatory diagnostic testing and genetic counseling (soster2023positivecfdnascreening pages 2-3, cong2025evaluatingtheeffectiveness pages 1-5). - Vaccination strategies and infection prevention based on immune status (mustillo2023clinicalpracticeguidelines pages 13-15, mustillo2023clinicalpracticeguidelines pages 16-17).

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in the retrieved evidence.

15. Model organisms

Mouse models referenced in retrieved evidence: - Dgcr8+/- mice: hippocampal neurogenesis deficits and cognitive/behavioral abnormalities consistent with miRNA-biogenesis mechanisms (cillo2024understandingthevariability pages 9-11). - Df(h22q11)/+ mouse model used to explore stress × deletion epigenetic effects in prefrontal cortex; overlapping genes and Wnt pathway signals described (jiao2024epigeneticfactorsin pages 1-4).

Limitations: The retrieved evidence did not include detailed named syntenic deletion lines (e.g., LgDel) or iPSC/organoid models; thus, this section is incomplete relative to the full field.

Recent developments (2023–2024 emphasis)

1. Standardized immunological management: 2023 clinical practice guidelines address major practice variation and provide explicit criteria for live vaccines, IGRT, and prophylaxis (Mustillo et al., 2023; URL: https://doi.org/10.1007/s10875-022-01418-y) (mustillo2023clinicalpracticeguidelines pages 13-15, mustillo2023clinicalpracticeguidelines pages 16-17).
2. Early detection expansion: Newborn TREC screening and improving prenatal cfDNA screening are emphasized in 2023 immunology review and cfDNA implementation papers (biggs2023chromosome22q11.2deletion pages 5-7, soster2023positivecfdnascreening pages 1-2).
3. Epigenetic/miRNA mechanisms and variability: 2024 review synthesizes evidence that phenotype arises from interactions between deleted genes and altered epigenetic regulation/miRNA biogenesis, including methylation episignatures (Cillo et al., 2024; URL: https://doi.org/10.3390/genes15030321) (cillo2024understandingthevariability pages 1-2, cillo2024understandingthevariability pages 9-11).

Evidence gaps in this tool-retrieved corpus (for KB completeness)

• ICD-10/ICD-11, MeSH, Orphanet, and MONDO identifiers were not explicitly present in the retrieved full texts, so they cannot be provided with citations here.
• Limited direct patient QoL and longitudinal pediatric natural history data in the retrieved documents.
• Limited explicit iPSC/organoid model and detailed model-organism resource citations.

Key references (URLs in evidence)

• Mustillo et al., 2023. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-022-01418-y (mustillo2023clinicalpracticeguidelines pages 1-2)
• Szczawińska-Popłonyk et al., 2023. IJMS. https://doi.org/10.3390/ijms24098317 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2)
• Biggs et al., 2023. Current Allergy and Asthma Reports. https://doi.org/10.1007/s11882-023-01071-4 (biggs2023chromosome22q11.2deletion pages 1-2)
• Soster et al., 2023. Frontiers in Genetics. https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
• Cillo et al., 2024. Genes. https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 1-2)
• Van et al., 2019. Genetics in Medicine. https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 4-6)
• Provenzani et al., 2022. International Review of Psychiatry. https://doi.org/10.1080/09540261.2022.2123273 (provenzani2022prevalenceandincidence pages 1-5)
• Malecki et al., 2026. Frontiers in Genetics. https://doi.org/10.3389/fgene.2026.1737027 (malecki2026delineatingthetrajectory pages 1-2)
• ClinicalTrials.gov NCT01220531 (Thymus Transplantation Safety-Efficacy) (NCT01220531 chunk 2)

References

1. (soster2023positivecfdnascreening pages 1-2): Erica Soster, Brittany Dyr, Jill Rafalko, Eyad Almasri, and Phillip Cacheris. Positive cfdna screening results for 22q11.2 deletion syndrome—clinical and laboratory considerations. Frontiers in Genetics, Mar 2023. URL: https://doi.org/10.3389/fgene.2023.1146669, doi:10.3389/fgene.2023.1146669. This article has 12 citations and is from a peer-reviewed journal.

2. (snihirova2022environmentalinfluenceson pages 1-2): Yelyzaveta Snihirova, David E. J. Linden, Therese van Amelsvoort, and Dennis van der Meer. Environmental influences on the relation between the 22q11.2 deletion syndrome and mental health: a literature review. Genes, 13:2003, Nov 2022. URL: https://doi.org/10.3390/genes13112003, doi:10.3390/genes13112003. This article has 9 citations.

3. (mustillo2023clinicalpracticeguidelines pages 2-4): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

4. (biggs2023chromosome22q11.2deletion pages 1-2): Sarah E. Biggs, Bailee Gilchrist, and Kathleen R. May. Chromosome 22q11.2 deletion (digeorge syndrome): immunologic features, diagnosis, and management. Current Allergy and Asthma Reports, 23:1-10, Mar 2023. URL: https://doi.org/10.1007/s11882-023-01071-4, doi:10.1007/s11882-023-01071-4. This article has 57 citations and is from a peer-reviewed journal.

5. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

6. (olsen2018prevalenceofrearrangements pages 1-3): Line Olsen, Thomas Sparsø, Shantel M Weinsheimer, Marcelo Bertalan Quintanilha Dos Santos, Wiktor Mazin, Anders Rosengren, Xabier Calle Sanchez, Louise K Hoeffding, Henriette Schmock, Marie Baekvad-Hansen, Jonas Bybjerg-Grauholm, Mark J Daly, Benjamin M Neale, Marianne G Pedersen, Esben Agerbo, Ole Mors, Anders Børglum, Merete Nordentoft, David M Hougaard, Preben Bo Mortensen, Daniel H Geschwind, Carsten Pedersen, Wesley K Thompson, and Thomas Werge. Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a danish population: a case-cohort study. The Lancet Psychiatry, 5:573-580, Jul 2018. URL: https://doi.org/10.1016/s2215-0366(18)30168-8, doi:10.1016/s2215-0366(18)30168-8. This article has 166 citations and is from a highest quality peer-reviewed journal.

7. (cillo2024understandingthevariability pages 1-2): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

8. (du2020thegeneticsand pages 3-5): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

9. (cillo2024understandingthevariability pages 7-8): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

10. (du2020thegeneticsand pages 1-2): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

11. (cillo2024understandingthevariability pages 3-5): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

12. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

13. (cillo2024understandingthevariability pages 2-3): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

14. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 5-7): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

15. (provenzani2022prevalenceandincidence pages 1-5): Umberto Provenzani, Stefano Damiani, Ilaria Bersano, Simran Singh, Antonella Moschillo, Tommaso Accinni, Natascia Brondino, Dominic Oliver, and Paolo Fusar-Poli. Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis. International Review of Psychiatry, 34:676-688, Sep 2022. URL: https://doi.org/10.1080/09540261.2022.2123273, doi:10.1080/09540261.2022.2123273. This article has 25 citations and is from a peer-reviewed journal.

16. (van2019allcausemortalityand pages 3-4): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

17. (van2019allcausemortalityand pages 1-2): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

18. (van2019allcausemortalityand pages 4-6): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

19. (van2019allcausemortalityand pages 3-3): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

20. (malecki2026delineatingthetrajectory pages 1-2): Sarah L. Malecki, Tracy Heung, Samantha Morais, Refik Saskin, Drew Wilton, Therese A. Stukel, Eyal Cohen, Amol A. Verma, and Anne S. Bassett. Delineating the trajectory of adult chronic diseases and healthcare use for 22q11.2 microdeletion in a general population context. Frontiers in Genetics, Feb 2026. URL: https://doi.org/10.3389/fgene.2026.1737027, doi:10.3389/fgene.2026.1737027. This article has 0 citations and is from a peer-reviewed journal.

21. (van202022q11.2microdeletionand pages 1-2): Lily Van, Tracy Heung, Sarah L. Malecki, Christian Fenn, Andrea Tyrer, Marcos Sanches, Eva W.C. Chow, Erik Boot, Maria Corral, Satya Dash, Susan R. George, and Anne S. Bassett. 22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine, 26:100528, Sep 2020. URL: https://doi.org/10.1016/j.eclinm.2020.100528, doi:10.1016/j.eclinm.2020.100528. This article has 32 citations and is from a peer-reviewed journal.

22. (cong2025evaluatingtheeffectiveness pages 5-10): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

23. (cong2025evaluatingtheeffectiveness pages 10-14): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

24. (biggs2023chromosome22q11.2deletion pages 5-7): Sarah E. Biggs, Bailee Gilchrist, and Kathleen R. May. Chromosome 22q11.2 deletion (digeorge syndrome): immunologic features, diagnosis, and management. Current Allergy and Asthma Reports, 23:1-10, Mar 2023. URL: https://doi.org/10.1007/s11882-023-01071-4, doi:10.1007/s11882-023-01071-4. This article has 57 citations and is from a peer-reviewed journal.

25. (soster2023positivecfdnascreening pages 2-3): Erica Soster, Brittany Dyr, Jill Rafalko, Eyad Almasri, and Phillip Cacheris. Positive cfdna screening results for 22q11.2 deletion syndrome—clinical and laboratory considerations. Frontiers in Genetics, Mar 2023. URL: https://doi.org/10.3389/fgene.2023.1146669, doi:10.3389/fgene.2023.1146669. This article has 12 citations and is from a peer-reviewed journal.

26. (cong2025evaluatingtheeffectiveness pages 1-5): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

27. (cong2025evaluatingtheeffectiveness pages 14-18): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

28. (mustillo2023clinicalpracticeguidelines pages 17-19): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

29. (mustillo2023clinicalpracticeguidelines pages 1-2): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

30. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

31. (jiao2024epigeneticfactorsin pages 1-4): Chuan Jiao, Fanny Demars, Anton Iftimovici, Qin He, Oussama Kebir, Anushree Tripathi, Hugo Turbé, Caroline Demily, Marie-Odile Krebs, Thérèse M Jay, and Boris Chaumette. Epigenetic factors in the 22q11.2 deletion syndrome in relation to stress and schizophrenia. MedRxiv, Jun 2024. URL: https://doi.org/10.1101/2024.06.23.24309352, doi:10.1101/2024.06.23.24309352. This article has 0 citations.

32. (cuturilo2026neurodevelopmentaldisordersin pages 1-2): Goran Čuturilo, Zorana Pavlović, and Danijela Drakulić. Neurodevelopmental disorders in children with 22q11.2 deletion syndrome and recommendations for pediatric follow-up. Medicinska istrazivanja, 59:35-39, Jan 2026. URL: https://doi.org/10.5937/medi0-58355, doi:10.5937/medi0-58355. This article has 0 citations.

33. (du2020thegeneticsand pages 5-6): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

34. (cillo2024understandingthevariability pages 9-11): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

35. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 10-12): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

36. (hui2020aminimumestimate pages 10-11): Lisa Hui, Alice Poulton, Eliza Kluckow, Anthea Lindquist, Briohny Hutchinson, Mark D Pertile, Leonard Bonacquisto, Lucy Gugasyan, Abhijit Kulkarni, James Harraway, Amanda Howden, Richard McCoy, Fabricio Da Silva Costa, Melody Menezes, Ricardo Palma-Dias, Debbie Nisbet, Nicole Martin, Michael Bethune, Zeffie Poulakis, and Jane Halliday. A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort. Human reproduction, 35:694-704, Mar 2020. URL: https://doi.org/10.1093/humrep/dez286, doi:10.1093/humrep/dez286. This article has 14 citations and is from a highest quality peer-reviewed journal.

37. (mustillo2023clinicalpracticeguidelines pages 13-15): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

38. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 12-13): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

39. (mustillo2023clinicalpracticeguidelines pages 16-17): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

40. (NCT01220531 chunk 2): Thymus Transplantation Safety-Efficacy. Sumitomo Pharma Switzerland GmbH. 2010. ClinicalTrials.gov Identifier: NCT01220531

Artifacts

• Edison artifact artifact-00